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Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular disease, including arterial
calcification. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in
elevations in serum calcium and phosphorus, increasing the risk of vascular calcification in dialysis patients. New vitamin D
receptor activators (VDRAs) have been developed and investigated with the rationale to treat high serum PTH levels, with
a reduced risk of hypercalcemia and hyperphosphatemia. Paricalcitol is a selective VDRA that suppresses PTH secretion with
minimal increases on serum calcium and phosphate. Moreover, paricalcitol prevents vascular calcification in experimental models
of renal failure, compared with calcitriol.
1. Introduction
Secondary hyperparathyroidism (SHPT) aﬀects less than half
of the approximately 320 000 haemodialysis (HD) patients
in the US who suﬀer from stage-V chronic kidney disease
(CKD) (also known as end-stage renal disease or end-stage
kidney disease) [41]. SHPT is characterized by abnormally
elevated serum concentrations of intact parathyroid hor-
mone (PTH), and abnormalities of serum calcium, phospho-
rous, and vitamin D concentrations. Inadequate treatment
of SHPT has been associated with the following conditions:
skeletal abnormalities (renal osteodystrophy), cardiovascu-
lar complications [1], infections and immunoregulatory
dysfunction [2], foot and extremity complications, and
anaemia. Patients on HD are at increased risk for fracture
(including hip fracture) and vascular calcification, which
results in significant morbidity (including hospitalization)
and mortality [3].
Diminished levels of vitamin D have been significantly
associated with an increased risk of vascular calcification in
patients with a moderate or high risk of coronary heart dis-
ease, even with normal renal function [4]. Age, race, diabetic
history, and log 1,25-D have been related to arterial mass
of coronary calcium and inversely correlated with calcium
phosphate mass. Furthermore, a cross-sectional examination
from NHANES (2001–2004) patient data demonstrated a
significant graded, inverse correlation between serum 25D
levels and the prevalence of peripheral arterial disease and
was independent of gender, age, race, and multivariable
adjustment [5].
Several studies in patients with CKD have now correlated
arterial calcification with the presence of coronary artery
disease [6], peripheral vascular disease [7], left ventricular
hypertrophy [6] and mortality. Increased pulse pressure, left
ventricular hypertrophy, and arrhythmias, resulting from
arterial stiﬀness, have been suggested as potential eﬀects of
arterial calcification that may lead to cardiovascular disease
and death.
CKD patients have a dramatically higher incidence of
cardiovascular morbidity and mortality compared to the
general population. Studies show that CVDmortality is 10 to
70 times greater in the dialysis population than in the general
age-matched cohort [8].
In the last 10 years, several studies pointed out that vas-
cular calcification is a major cause of cardiovascular disease
in the dialysis population. In CKD patients, high levels of
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plasma calcium, serum phosphate, and PTH play a critical
role in the pathogenesis of cardiovascular events [9]. Nasri et
al. [10] analyzed the influence of PTH on myocardial func-
tion. In their cross-sectional study in hemodialysis patients,
they determined that excess PTH played a significant role
in the development of LVH and reduced left ventricular
ejection fraction. In a decade-long retrospective study, Dai
et al. found a 52% prevalence of severe LVH among ESRD
patients. Ha et al. [11] further extended the links between
LVH and CKD, finding an 87% prevalence of concentric
and eccentric LVH among predialysis patients. Foley et
al. corroborated the results in a decade-long prospective
study, finding that 80% of the 433 patients initiating dialysis
presented with LVH on echocardiography. The relationship
between elevated PTH and LVH was further explored in a
retrospective study by Goto et al. [12] who determined that
parathyroidectomy in CKD patients with advanced SHPT led
to a significant improvement of left ventricular ejection, frac-
tion, and function. Hyperphosphatemia and hypercalcemia
have been shown to promote calcification of the vascula-
ture, myocardium, and cardiac valves. Vascular calcification
manifested in reduced vessel wall elasticity, increased intima-
media layer thickness, and enhanced pulse-wave velocity—
has been linked to LVH—and occurs with increased severity
in dialysis patients versus non-CKD patients.
Patients develop extensive medial calcification, which
causes increased arterial stiﬀness and high morbidity and
mortality due to cardiovascular events [13]. A variety of
risk factors are associated with vascular calcification in
dialysis patients (time on dialysis, uremic toxins, history of
diabetes, inflammation), but abnormal ties in bone mineral
metabolism may play a critical role [14]. In fact, elevated
serum phosphate, calcium-phosphate product, and PTH
levels contribute to vascular calcification, although their roles
are incompletely understood [15, 16].
Elevations of serum phosphate and calcium-phosphate
product levels may worsen cardiovascular events in the
uremic population, through a progressive increase in calcium
deposition in the coronary arteries and heart valves [8].
Furthermore, calcium-containing phosphate binders can
increase calcium load [17]. In haemodialysis children and
young adults, Goodman et al. [18] showed a correlation
between coronary artery calcification detected by electron
beam computed tomography (EBCT) and years on dialysis,
serum phosphorus, calcium-phosphate product levels, and
daily intake of calcium.Moreover, experimental observations
in uremic rats [19, 20] and in dialysis patients [21] indicate
that the calcium and aluminium-free phosphate binder,
Sevelamer HCl, reduced the progression of cardiovascular
calcification observed in a control group treated with
calcium-based phosphate binders [20].
2. The Role of Paricalcitol on CKD-MBD
Prevention and Treatment
Prevention and treatment of SHPT commonly requires
control of both phosphate and 1,25(OH)2D levels in serum.
Phosphate levels are usually controlled by reducing dietary
phosphate intake, by dialysis, and by using phosphate-
binders. 1,25(OH)2D eﬀectively suppresses PTH production
and improves bone histology in some patients [22].
The therapeutic use of 1,25(OH)2D in CKD mainly aims
to raise intestinal absorption of calcium, to protect bone
against osteomalacia and to control parathyroid function.
However, also the function of other organs expressing
VDR, as kidney, pancreas, myocardium, and testis, might
be improved by vitamin D administration. 1,25(OH)2D
inhibitory eﬀect on PTH synthesis and parathyroid
hyperplasia is well established in CKD. Vitamin D analogues
with a lower hypercalcemic and hyperphosphatemic activity,
are now available as an eﬃcient alternative to 1,25(OH)2D
treatment. Furthermore, normal serum levels of 25(OH)D
are relevant for the prevention or treatment of SHPT, due
to the capacity of 25(OH)D to support renal 1α-hydroxylase
activity or the synthesis of active vitamin D metabolites
diﬀerent from 1,25(OH)2D.
Clinical targets for serum concentrations of phosphate,
calcium, and PTH have been proposed in the 2003 guidelines
proposed by the Kidney Dialysis Outcomes Quality Initiative
(K/DOQI) Work Group [23]. Target for plasma concen-
trations of PTH increases according to creatinine clearance
because patients develop a progressive tissue resistance to
PTH explained by a diminished expression of PTH receptors
and by 1,25(OH)2D deficiency or resistance [24, 25]. The
low target for calcium concentrations aims to avoid calcium
overload and excessively high calcium x phosphate product.
A particular bone complication of the therapy with
vitamin Dmetabolites occurs in case of excessive parathyroid
suppression. As defined in the K/DOQI guidelines, the target
for PTH concentration is 150–300 pg/mL in end-stage CKD.
The new K/DIGO guidelines proposed a new target for
serum PTH levels [26], but if the values of circulating
PTH are suppressed below these limits, bone cells become
quiescent and bone remodelling is far slowed [27]. The
histology pattern of these functional alterations is adynamic
bone disease, characterized by decreased number of bone
cells, bone metabolic inactivity, and reduced bone formation
rate [25]. The mechanism of adynamic bone disease is
unknown. The clinical consequences of adynamic bone dis-
ease may be an increased fracture risk while its relationship
with osteoporosis is still debated [28]. At the opposite,
osteomalacia may develop in case of 1,25(OH)2D deficiency,
even though the toxic eﬀect of aluminum overload has
been the most frequent cause of osteomalacia in dialysis
population till some years ago [29, 30].
Several new vitamin D analogues have been developed
and investigated with the rationale to treat secondary
HPT with a reduced risk of hypercalcemia and hyper-
phosphatemia in CKD patients. Vitamin D analogues have
variable aﬃnity for the components of the vitamin D system,
including the vitamin D-binding protein and the nuclear
VDR. Some of the eﬀects are genomic and mediated through
changes in the structural configuration of the vitamin D-
VDR complex or in the aﬃnity of the vitamin D-VDR
complex for the key response elements in various target
genes. There are currently 3 vitamin D analogues approved
for use in CKD patients with secondary HPT in the US,
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1,25-dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT),
1,25-dihydroxy-19-norvitamin D2 (19-norD2, paricalcitol),
and 1α-hydroxyvitamin D2 (1αOHD2).
Three identical, 12-week studies determined that par-
icalcitol was safe and eﬀective in suppressing serum PTH
levels in 78 HD patients without significantly increasing
serum calcium and phosphorus levels. The mean percent-
age decrease in iPTH was 60%, and calcium levels rose
slightly but remained within the normal range. Changes in
phosphate from baseline to study end were not significantly
diﬀerent between the group treated with paricalcitol and the
group treated with placebo.
First, Martin et al. [31] reported the outcomes of up to 1
year of therapy with paricalcitol in 164HD patients. Parical-
citol rapidly suppressed PTH, with the mean iPTH reaching
a target of 150–300 pg/mL by month 5. Furthermore, 19-
norD2 had minimal eﬀects on calcium and phosphate.
Most (70%) of the episodes of hypercalcemia (>11.5mg/dL)
that occurred did so when iPTH was suppressed below
150 pg/mL.
Second, a 12-week study by Martin et al. [32] compared
PTH suppression and calcium/phosphate outcomes when
125HD patients were given doses of paricalcitol that were
based on the patient’s dry weight or on the serum level of
iPTH. Both regimens were eﬀective in reducing iPTH to the
target of four consecutive weeks of 30% or greater reductions
from baseline. The patients receiving the dosing regimen
based on iPTH level reached this target significantly faster
than those on the weight-based regimen (31 versus 45 days,
P = .0306). No incidences of hypercalcemia occurred in
either group.
Third, Llach and yudd [30] proved that 19-norD2 is
eﬀective in suppressing PTH in 37HD calcitriol-resistant
patients. This study showed that using 3mcg of paricalcitol
for each 1mcg of calcitriol that the patient had previously
received (a 1 : 3 ratio) resulted in a decline in mean iPTH
from 836 to 341 pg/mL after 2 months. Clearly the above
studies establish that 19-norD2 rapidly suppresses PTH with
no significant diﬀerence in the incidence of hyperphos-
phatemia or hypercalcemia compared to placebo.
Paricalcitol has also been directly compared with cal-
citriol in an international study involving HD 263 patients.
This study showed that paricalcitol reduced iPTH 50% or
more from baseline and did so significantly faster than
calcitriol. Patients receiving paricalcitol had significantly
fewer sustained episodes of hypercalcemia and/or increased
Ca× P product [33]. In addition, a historical study examined
the records of 67,399 patients who had been treated exclu-
sively with calcitriol or paricalcitol. Patients were evaluated
over a 2-year period until one of the following occurred:
death, a switch to another vitamin D formulation, renal
transplantation, or transfer to another facility. This study
showed a statistically significant diﬀerence in survival rate
in favor of paricalcitol over calcitriol [34]. Furthermore, in
patients taking 19-norD2 a reduced hospitalization rate was
observed [35]. These findings will need to be supported by
prospective trials before definitive conclusions can be made.
The mechanism for paricalcitol’s low calcemic eﬀect is
due to reduced stimulation of intestinal calcium transport
Paricalcitol
↓ Bone disease
↓ Left ventricular
hypertrophy
↓ Proteinuria ↓ Vascular
calcification
↓ Inflammation
↓Hypertension
↓ Visceral
calcification
↓Congestive
heart failure
Figure 1
proteins (e.g., calbindin, CAT, and PMAT) compared to
calcitriol, [36, 37] thus conferring a selective activator
function [38].
With the ubiquitous presence of the VDR in many
tissues, it is of little wonder that the role of the VDR
is multifaceted in providing tissue-specific responses. The
impact of selective VDR activators on vascular calcification
is multifaceted in that in vivo and clinical outcomes show
variable results depending on the clinical circumstance and
dose of VDR activator administered [39]. Although VDR
activationmaymitigate the eﬀects of uremia-induced arterial
calcification, emerging data support a potential role for VDR
activation in preventing or ameliorating the pathogenesis of
atherosclerosis.
These are a number of examples of many selective VDR
activator eﬀects on cardiovascular structure and function
that, if borne out in humans, have the potential to improve
clinical outcomes in CKD-MBD (Figure 1).
Low or clinically relevant doses of VDR activators
correlate with decreased deposition of calcium and improved
therapeutic outcomes, whereas high doses may actually
induce vascular calcification. In 28-week-old mice, therapeu-
tically relevant doses of calcitriol and paricalcitol reduced
aortic calcium levels and aortic gene expression of osterix,
Msx2, core binding factor (alpha)1 (Cbfa1/Runx-2), and
osteocalcin, markers for progression of vascular calcification;
while an elevated dose of 1,25-D or paricalcitol actually
stimulated vascular calcification [40]. In a study of uremic
rats, doxercalciferol produced marked increases in aortic
calcification and aortic mRNA and protein expression of
Runx2 and osteocalcin, whereas paricalcitol had no eﬀect on
these endpoints [41].
VDR activation has been shown to have a number of
potential ameliorative eﬀects on both inhibitors and inducers
of calcification. The addition of VDR activators suppresses
calcification inducers type I collagen, bone sialoprotein, IL-
1β, and tumor necrosis factor (TNF)-α, as well as bone
morphogenetic protein (BMP)-2 [42]. In addition, calcifica-
tion inhibitors matrix Gla protein (MGP), osteopontin, and
osteocalcin were upregulated by VDR activator treatment
[43]. The same is true for type IV collagen.
Another hypothetical mechanism of VDR activation
impact on cardiovascular outcome is an inappropriate acti-
vation of the renin-angiotensin-aldosterone system (RAAS),
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which plays a central role in the regulation of blood pressure,
electrolyte, and volume homeostasis and may represent a
major risk factor for hypertension, heart attack, and stroke.
Evidence from clinical studies has demonstrated an inverse
relationship between circulating vitamin D levels and the
blood pressure and/or plasma renin activity [44].
3. Conclusions
Themodern strategies to prevent SHPT in CKD patients give
great relevance to vitamin D replacement therapy. A sound
approach to treatment requires taking into account many
factors, including stage of CKD, underlying renal disorder,
levels of circulating PTH, bone status, vitamin D deposits,
and serum calcium and phosphate levels. The aim of vitamin
D replacement therapy is to prevent SHPT from the early
stages of CKD, because once parathyroid hyperplasia and
osteodystrophy develop, they cannot be completely reverted.
Because nephrologists have largely focused their attention on
dialysis patients, unfortunately few studies have analyzed the
outcome of vitamin D therapy in nonuremic patients.
The therapeutic strategies for SHPT are now changing.
The availability of selective VDRAs may warrant inhibition
of parathyroid glands with lower eﬀect on calcium and
phosphate levels and perhaps reduces mortality of dialysis
patients. Paricalcitol is a selective VDRA with minor impact
on serum Ca and P levels. Paricalcitol is growly used in
dialysis patients for its eﬃcacy and safety in the treatment
and prevention of SHPT in this population. Recent studies
demonstrated that therapy with paricalcitol injection is
associated with improved survival, fewer hospitalizations,
and shorter hospital stays in HD patients compared with
calcitriol, even if prospective clinical trials are ongoing.
Additionally, subjects on HD who did not receive active
vitamin D had higher all-cause and cardiovascular mortality
compared with subjects who received any form of active
vitamin D.
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